Printed by: Le Tran

Official Date: Official as of 01-Nov-2020

Document Type: GENERAL CHAPTER

@2021 USPC

1

# (641) COMPLETENESS OF SOLUTION

### Add the following:

▲The purpose of these methods is to verify that one or more materials are completely dissolved in a solution. These methods may be used to verify the descriptive solubility of a material according to the solubility table in *General Notices*, 5.30 Description and Solubility.

To verify the descriptive solubility, use the maximum amount of solvent specified for the descriptive solubility in the solubility table (see *General Notices*, 5.30 Description and Solubility). For example, for "soluble" use 30 parts of solvent. Into this amount of solvent, add 1 part of solute weighed accurately to 0.5%. Unless otherwise specified in the monograph, completeness of solution should be evaluated at 25°.

Evaluation of the completeness of solution, as described in this chapter, does not provide a precise measure of compound solubility. The descriptive solubility terms above should also not be confused with the terms "high solubility" and "low solubility" as applied to drug substances in the *Biopharmaceutical Classification System.*<sup>1, 2</sup> For more information on precise solubility measurements and biorelevant solubility determinations, see *Solubility Measurements* (1236).

Unless otherwise directed in the individual monograph, use Method I. ▲ (USP 1-Aug-2020)

#### Change to read:

# **^METHOD** I<sub>▲</sub> (USP 1-AUG-2020)

Place the quantity of the substance specified in the individual monograph in a meticulously cleansed, glass-stoppered, 10-mL \*color-comparison tube. \*\(\(\Delta\)\(\text{USP 1-Aug-2020}\)\) Using the solvent that is specified in the monograph or on the label of the product, fill the \*\(\text{color-comparison}\) tube to the 10-mL mark. \*\(\Delta\)\(\text{USP 1-Aug-2020}\)\) Shake gently to dissolve: the solution is not less clear than an equal volume of the same solvent contained in a \*\(\text{matched color-comparison}\) tube \*\(\Delta\)\(\text{USP 1-Aug-2020}\)\) and examined similarly \*\(\text{(see Visual Comparison}\)\(\delta\)\)\(\text{USP 1-Aug-2020}\)

### Add the following:

## **^METHOD II**

Place the quantity of the substance specified in the individual monograph into a meticulously cleansed 10-mL flask. Add 10 mL of the solvent that is specified in the monograph or on the label of the product. Shake gently to dissolve. Transfer the solution to a suitable measurement tube and measure the turbidity of the prepared solution per *Nephelometry and Turbidimetry* (855). The acceptance criterion is that the turbidity of the sample preparation is NMT that of *Reference suspension II* in (855), *Table 1* [NMT 6 nephelometric turbidity units (NTU)]. (USP 1-Aug-2020)

<sup>1</sup> US Food and Drug Administration. Guidance for industry. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Rockville, MD: US Food and Drug Administration; December 2017.

<sup>&</sup>lt;sup>2</sup> USP. Reagents and Reference Tables, Solutions, Buffer Solutions, 4. Standard Buffer Solutions, 4.1 Preparation. In: *USP–NF*. Rockville, MD: USP; 1 May 2018. https://online.uspnf.com/uspnf/document/GUID-0E4CE941-0762-456C-94B0-9209A58834FC.